BRAF and thyroid cancer, nonmedullary, 2: The BRAF V600E mutation, known for its high specificity in malignancy, is detected in approximately 61.7% of papillary thyroid carcinoma (PTC), 1.7% of follicular thyroid carcinoma (FTC), 19–45% of anaplastic thyroid carcinoma and 19–33% of poorly differentiated thyroid carcinoma (PDTC) (6).